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CapsaicinThe activation of nitric oxide (NO) production is an analgesic mechanism shared by drugs such as morphine and
diclofenac. Therefore, the controlled release of low amounts of NO seems to be a promising analgesic approach. In
the present study, the antinociceptive effect of the ruthenium NO donor [Ru(bpy)2(NO)SO3](PF6) (complex I)
was investigated. It was observed that complex I inhibited in a dose (0.3–10 mg/kg)-dependent manner the acetic
acid-induced writhing response. At the dose of 1 mg/kg, complex I inhibited the phenyl-p-benzoquinone-induced
writhing response and formalin- and complete Freund's adjuvant-induced licking andﬂinch responses. Additionally,
complex I also inhibited transient receptor potential cation channel subfamily V member 1 (TRPV1)-dependent
overt pain-like behavior induced by capsaicin. Complex I also inhibited the carrageenin-induced mechanical
hyperalgesia and increase of myeloperoxidase activity (MPO) in paw skin samples. The inhibitory effect of complex
I in the carrageenin-induced hyperalgesia, MPO activity and formalin was prevented by the treatment with ODQ,
KT5823 and glybenclamide, indicating that complex I inhibits inﬂammatory hyperalgesia by activating the cGMP/
PKG/ATP-sensitive potassium channel signaling pathway. The present study demonstrates the efﬁcacy of a novel
ruthenium NO donor and its analgesic mechanisms.
© 2013 Elsevier Inc. Open access under the Elsevier OA license.1. Introduction
The animal models evaluate two main symptoms of pain: i) overt
nociception/overt pain-like behavior or ii) hyperalgesia and allodynia.
In overt nociception/overt pain-like behavior, an inﬂammatory stimulus
induces a declared behavior such as paw ﬂinch or licking and abdominal, aspartate aminotransferase;
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vier OA license.contortions (writhing) without further mechanical or thermal external
stimuli. This declared behavior occurs because the overt nociceptive
stimuli activate or induce fast production of endogenous mediators
that activate the nociceptors (Collier et al., 1968; Dubuisson and
Dennis, 1977; Pavao-de-Souza et al., 2012; Ribeiro et al., 2000; Verri et
al., 2008, 2006).
Hyperalgesia is deﬁned as an increase of pain sensation caused by a
stimulus that normally induces pain and allodynia as pain due to a stim-
ulus that does not normally provoke pain. Both result from the sensitiza-
tion of nociceptors in which, for instance, inﬂammatory mediators
activate second messenger pathways resulting in the lowering of the
nociceptor threshold and increasing neuronal membrane excitability
(Pavao-de-Souza et al., 2012; Verri et al., 2006).
Experimentally, peripheral pharmacological control of inﬂammatory
hyperalgesia is based on two strategies. The ﬁrst is the prevention of
nociceptor sensitization, which can be achieved with non-steroidal
anti-inﬂammatory (aspirin-like) drugs that inhibit prostaglandin syn-
thesis (Ferreira, 1972). The second strategy is the direct blockade of
the current nociceptor sensitization, which can be achieved by the use
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al., 2010; Ferreira et al., 1991b; Lorenzetti and Ferreira, 1985; Sachs et al.,
2004). Thesedrugs are able to inhibit the already establishedhyperalgesia
induced by PGE2 (Cunha et al., 2010, 2012; Ferreira et al., 1991a;
Lorenzetti and Ferreira, 1985; Sachs et al., 2004). Moreover, several
studies have demonstrated that the antinociceptive mechanism of these
drugs depends on the activation of the L-arginine/NO/guanosine 3,
5-cyclic monophosphate (cGMP)/protein kinase G (PKG)/ATP-sensitive
potassium channel pathway (Cunha et al., 2010, 2012; Ferreira et al.,
1991a; Mizokami et al., 2012; Napimoga et al., 2008; Sachs et al., 2004;
Santodomingo-Garzon et al., 2006; Vivancos et al., 2003). However, the
control of inﬂammatory pain is still a major challenge because of the
deleterious side effects attributed to the prolonged use of NSAIDs and
opioids, their ineffectiveness in some cases and receptor desensitization
in the case of opioids.
Nitric oxide is produced in mammalian cells from L-arginine and
oxygen by three isoforms of the enzyme NO synthase (NOS): neuro-
nal (nNOS or type I), inducible (iNOS or type II) and endothelial
(eNOS or type III) (Alderton et al., 2001; Moncada et al., 1991). An
important difference between the isoforms of NOS is that the consti-
tutive type produces low NO concentrations in the nmol L−1 range,
while the inducible form produces NO in the μmol L−1 range
(Pagliaro, 2003). Accordingly, nitric oxide plays an important role in a
variety of physiological functions, such as blood pressure control
(Moncada and Higgs, 1993), neurotransmission (Bredt et al., 1990;
Garthwaite, 1991), immunological and inﬂammatory responses (Hibbs
et al., 1988; Rees et al., 1989; Silva et al., 2007) and antioxidant action
(McCleverty, 2004;Wink andMitchell, 2003). These effects are quite de-
pendent on the local NO bioavailability and concentration (Wink and
Mitchell, 1998). Therefore, intense efforts have been devoted to develop
new compounds that deliver NO efﬁciently and in a controlled manner
(Tfouni et al., 2012). In models of nociception, it is consensus that NO ac-
tivates the cGMP/PKG/ATP-sensitive potassium channel signaling path-
way (Kawabata et al., 1994; Li and Qi, 2010; Sousa and Prado, 2001;
Tegeder et al., 2002; Vivancos et al., 2003), which is also the signaling
pathway activated by the peripheral action of opioids (Cunha et al.,
2010, 2012). Therefore, NO donors could be used to achieve similar
effects as of peripheral opioids without the side effects related to opioid
receptor activation.
In this context, our group has synthesized a nitrosyl ruthenium com-
plex that donates NO, [Ru (bpy)2(NO)SO3](PF6) (Silva et al., 2007) here
named as complex I.Wehave previously demonstrated thatmice treated
with complex I are more resistant to paracoccidioidomycosis infection,
which was observed as prolonged survival with reduced leukocyte
recruitment and TNFα production in the lung and liver as well as in-
creased production of the anti-inﬂammatory cytokine IL-10 (Pavanelli
et al., 2011). Furthermore, the complex I presents additional biological
activities against several diseases suchas in vitro and in vivo trypanocidal
activities (Silva et al., 2007) and beneﬁcial effects in amodel of ischemia/
reperfusion in the brain (Campelo et al., 2012).
Some interesting characteristics of ruthenium NO donors are the re-
lease of NO through electrochemical, photochemical and chemical pro-
cesses (Silva et al., 2007). The rate constant for the NO release induced
by thiols is pH-dependent and increases by raising the pH, due to the
acid–base equilibrium of thiol group of the cysteine residue (Silva et al.,
2011). In this respect, ruthenium compounds could be useful as delivery
or scavenging agents for molecules that have a crucial role in physiology
(Tfouni et al., 2012). Moreover, NO-donors are of great interest due to
their outstanding properties, such as the low cytotoxicity against host
cells, water solubility, stability to air oxidation and tailoring reactivity
possibilities of the coordinated NO (Borges et al., 1998; Lopes et al.,
1998; Toledo et al., 2002; Tfouni et al., 2012).
Considering the information above, in the present study we inves-
tigated the mechanism involved in the antinociceptive effect of
[Ru(bpy)2(NO)SO3](PF6) in models of overt pain-like behavior and
in carrageenin-induced mechanical inﬂammatory hyperalgesia. Therole of cGMP/PKG/ATP-sensitive potassium channel signaling pathway
was also investigated.
2. Material and methods
2.1. Animals
Male Swiss mice (25–30 g) from the Universidade Estadual de
Londrina, Paraná, Brazil, were used in this study. Mice were housed in
standard clear plastic cages with free access to food and water and a
light/dark cycle of 12:12 h and kept at 21 °C. Different investigators pre-
pared the solutions, treated the mice, injected the stimulus and quanti-
ﬁed the nociceptive behaviors. All behavioral testing was performed
between 9 am and 5 pm in a temperature-controlled room. Animal
care andhandling procedureswere in accordancewith the International
Association for the Study of Pain (IASP) guidelines andwith the approval
of the Ethics Committee of the Universidade Estadual de Londrina. All
efforts were made to minimize the number of animals used and their
suffering. It is noteworthy that different experimenters prepared the
solutions, made the administrations and performed the evaluation of
pain-like behavior.
2.2. Drugs
The following materials were obtained from the sources indicat-
ed: acetic acid from Mallinckrodt Baker, S.A. (Mexico City, Mexico);
glybenclamide, capsaicin, KT5823 (2,3,9,10,11,12-hexahydro-10R-
methoxy-2,9-dimethyl-1-oxo-9S,12R-epoxy-1diindolo [1,2,3-fg:3′,2′,
1′-kl] pyrrolo [3,4-i][1,6]benzodiazocine-10-carboxylic acid, methyl
ester) were obtained from Sigma-Aldrich (St. Louis, MO, USA). ODQ
(1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one) was obtained from
Calbiochem (San Diego, CA, USA). Carrageenin from FMC Corporation
(Philadelphia, PA), phenyl-p-benzoquinone and CFA from Sigma (St.
Louis, MO), formalin from Merck (Darmstadt, Germany). The selected
doses of drugs were chosen based on pilot studies and previous data
of our laboratory. We detected that the doses of drugs used do not
alter the nociceptive response per se, and inhibit the respective stan-
dard stimulus (Cunha et al., 2010; Mizokami et al., 2012; Vale et al.,
2007; Valerio et al., 2009; Verri et al., 2008).
2.3. Synthesis of rutheniumNO donor [Ru(bpy)2(NO)SO3](PF6) (complex I)
The ruthenium NO donor [Ru(bpy)2(NO)SO3](PF6) namely complex I
was synthesized and characterized as we previously described (Silva et
al., 2007). Elemental analysis of hydrogen, carbon, and nitrogen was car-
ried out using an EA 1110 CHNS-O CE instrument. Analysis of ruthenium
was performed as described elsewhere (Clarke, 1978), using a Polarized
Zeeman atomic absorption spectrophotometer, Hitachi (model Z-8100),
with a Hitachi Hollow Cathode Lamp, 12 mA, and k=349.9 nm. UV
visible measurements were performed in a 1.0 cm quartz cell in a
Hewlett-Packard diode arraymodel 8452A spectrophotometer. IR spectra
were recordedwith a BomemFTIR,modelMB-102, spectrophotometer in
the 400–4000 cm−1 range, with the sample supported in potassium
bromide pellets. A polarographic analyzer/stripping voltammeter model
264A from Princeton Applied Research attached to a microcomputer
and employing Microquimica Eletrochemical software was used for the
electrochemical measurements. The electrochemical cell used was a con-
ventional three-electrode type with an aqueous saturated calomel elec-
trode as a reference electrode and a glassy carbon and platinum wire as
working and auxiliary electrodes, respectively (Pavanelli et al., 2011).
2.4. Writhing response tests
The PBQ (Emele and Shanaman, 1967) and acetic acid (Collier et
al., 1968) induced writhing models were performed as previously de-
scribed (Pavao-de-Souza et al., 2012). Mice were pretreated with
Fig. 1. [Ru(bpy)2(NO)SO3](PF6) (complex I) inhibits overt pain-like behavior induced
by acetic acid and phenyl-p-benzoquinone (PBQ). Mice received subcutaneous treat-
ment with complex I (0.3–10 mg/kg or 1.0 mg/kg) or vehicle (saline — indicated as
zero) 40 min before acetic acid (0.8%) (panel A) or PBQ (1890 μg/kg) (panel B) intra-
peritoneal stimulus. The vehicle of acetic acid was saline and PBQ 2% DMSO in saline.
The cumulative number of abdominal contortions (writhing score) was evaluated for
over 20 min. Results are presented as means±SEM of 6 mice per group, and are rep-
resentative of 2 separate experiments. ⁎Pb0.05 compared to the saline group;
#Pb0.05 compared to the acid acetic or PBQ group (one-way ANOVA followed by
Tukey's test).
Fig. 2. [Ru(bpy)2(NO)SO3](PF6) (complex I) inhibits overt pain-like behavior induced
by complete Freund's adjuvant (CFA). Mice received subcutaneous treatment with
complex I (1.0 mg/kg, s.c.) or vehicle (saline — indicated as zero) 40 min before CFA
(10 μL) intraplantar (i.pl.) stimulus. The time spent licking the paw (panel A) and the
total number of paw ﬂinches (panel B) were evaluated for over 30 min, respectively.
Results are presented as means±SEM of 6 mice per group, and are representative of 2
separate experiments. ⁎Pb0.05 compared to the saline group; #Pb0.05 compared to the
CFA group and saline group (panel A) or compared to the CFA group (panel B) (one-way
ANOVA followed by Tukey's test).
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40 min before i.p. stimulus with PBQ diluted in DMSO 2%/saline
(1890 μg/kg), acetic acid (0.8% v/v, saline, 10 mL/kg) or vehicle.
After all treatments, each mouse was placed in a large glass cylinder
and the intensity of nociceptive behavior was quantiﬁed by counting
the total number of writhes occurring between 0 and 20 min after
stimulus injection. The writhing response consists of a contraction
of the abdominal muscle together with a stretching of hind limbs.
The intensity of the writhing response was expressed as the cumula-
tive writhing score over 20 min.
2.5. CFA test
The number of paw ﬂinches and time spent licking the paw were
determined between 0 and 30 min after intraplantar injection of
10 μL of complete Freund's adjuvant (CFA). Results were expressed
by the total number of ﬂinches and licks performed during 30 min
(Mizokami et al., 2012).
2.6. Capsaicin test
The procedure usedwas similar to that described previously (Otuki et
al., 2005). After an adaptation period, 20 μL of capsaicin (5.2 nmol/paw
prepared in saline) was injected intraplantar (i.pl.) under the surface of
the right hind paw. Animalswere observed individually for 5 min follow-
ing capsaicin injection. The amount of time spent licking and ﬂinches in
the injected paw was considered as indicative of nociception.
2.7. Formalin Test
The number of paw ﬂinches and time spent licking the paw were
determined between 0 and 30 min after intraplantar injection of
25 μL of formalin 1.5%, as previously described. The period was divided
in intervals of 5 min and clearly demonstrated the presence of the ﬁrst
and second phases, which are characteristic of the method (Dubuisson
and Dennis, 1977).
2.8. Mechanical nociceptive paw test
Mechanical hyperalgesia was tested in mice as previously reported
(Cunha et al., 2004). In a quiet room, mice were placed in acrylic cages
(12×10×17 cm) with wire grid ﬂoors 15–30 min before the start of
testing. The test consisted of evoking a hind paw ﬂexion reﬂex with a
handheld force transducer (electronic anesthesiometer, IITC Life Science,
Woodland Hills, CA) adapted with a 0.5 mm2 polypropylene tip. The
investigator was trained to apply the tip perpendicularly to the central
area of the plantar hind paw with a gradual increase in pressure. The
gradual increase in pressure was manually performed in blinded exper-
iments. The upper limit pressurewas 15 g. The end-pointwas character-
ized by the removal of the paw followed by clear ﬂinching movements.
After paw withdrawal, the intensity of the pressure was automatically
recorded, and the ﬁnal value for the responsewas obtained by averaging
three measurements. The animals were tested before and after treat-
ments. The results are expressed by delta (Δ) withdrawal threshold
(in g) calculated by subtracting the zero-time mean measurements
from the mean measurements 1.3 and 5 h after stimulus. Withdrawal
threshold was 9.1±0.4 g (mean±SEM; n=30) before injection of
the hyperalgesic agents (e.g., carrageenin).
2.9. Myeloperoxidase (MPO) assay
Neutrophil migration to the hind paw plantar tissues of mice was
evaluated using a myeloperoxidase (MPO) kinetic–colorimetric assay
as previously described (Bradley et al., 1982; Casagrande et al., 2006).
Samples of subcutaneous plantar tissue were collected in 50 mM
K2HPO4 buffer (pH 6.0) containing 0.5% hexadecyltrimethylammoniumbromide (HTAB) and kept at−80 °C until use. Samples were homoge-
nized using a Polytron (PT3100), centrifuged at 16,100 g for 4 min,
and the resulting supernatantwas assayed forMPO activity spectropho-
tometrically at 450 nm(Spectramax), with three readings in 1 min. The
MPO activity of samples was compared to a standard curve of neu-
trophils. Brieﬂy, 15 μL of sample was mixed with 200 μL of 50 mM
phosphate buffer, pH 6.0, containing 0.167 mg/mL O-dianisidine
dihydrochloride and 0.0005% hydrogen peroxide. The results are
presented as MPO activity (number of neutrophils×104 per mg of
tissue).2.10. Measurement of Motor Performance
In order to discard possible nonspeciﬁc muscle relaxant or sedative
effects of complex I, mice motor performance was evaluated using the
rota-rod test (Mizokami et al., 2012; Valério et al., 2007). The apparatus
Fig. 3. [Ru(bpy)2(NO)SO3](PF6) (complex I) inhibits overt pain-like behavior induced
by capsaicin. Mice received subcutaneous treatment with complex I (1.0 mg/kg, s.c.)
or vehicle (saline — indicated as zero) 40 min before capsaicin (5.2 nmol, 20 μL)
intraplantar (i.pl.) stimulus. The time spent licking the paw (panel A) and the total
number of paw ﬂinches (panel B) were evaluated for over 5 min. Results are presented
as means±SEM of 6 mice per group, and are representative of 2 separate experiments.
⁎Pb0.05 compared to the saline group; #Pb0.05 compared to the capsaicin group
(one-way ANOVA followed by Tukey's test).
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partments by disks 25 cm in diameter (Ugo Basile, model 7600). The
bar rotated at a constant speed of 22 rpm. The animals were selected
24 h previously by eliminating those mice that did not remain on the
bar for two consecutive periods of 120 s. Animals were treated with
vehicle (saline) or complex I (3 mg/kg, s.c.), and testing was performed
1, 3, and 5 h after treatment. The cutoff time used was 120 s.2.11. Acute toxicity
To investigate the potential acute toxicity caused by complex I, the
mice received a single subcutaneous dose of complex I (3 mg/kg) or
vehicle (saline). Five hours after the treatment, the animals were
anesthetized prior to blood collection by heart puncture into heparin
containing tubes. Plasma was obtained by centrifugation at 0.4 rcf for
10 min. Plasma aspartate (AST) and alanine (ALT) aminotransferases
activities were used as biochemical markers for early acute hepatic
damage. These assays were performed using a diagnostic kit from
Labtest (Lagoa Santa, Minas Gerais, Brazil) (Mizokami et al., 2012).Fig. 4. [Ru(bpy)2(NO)SO3](PF6) (complex I) inhibits overt pain-like behavior induced by for
(saline) 40 min before formalin (1.5%, 25 μL) intraplantar (i.pl.) stimulus. The vehicle of form
ﬂinches (panel B) were evaluated for over 30 min and expressed in intervals of 5 min. Re
separate experiments. ⁎Pb0.05 compared to the saline group; #Pb0.05 compared to the for2.12. Statistical analysis
Results are presented as means±SEM of measurements made on 6
mice in each group. Two-way analysis of variance (ANOVA) was used
to compare the groups and doses at all times (curves). The analyzed
factors were treatments, time and time versus treatment interaction.
When there was a signiﬁcant time versus treatment interaction, one-
way ANOVA followed by Tukey's t-test was performed for each time.
On the other hand, when the nociceptive responses were presented as
total writhing within 20 min or at indicated time period, the differences
between responses were evaluated by one-way ANOVA followed by
Tukey's t-test. Statistical differences were considered to be signiﬁcant
at Pb0.05.3. Results
3.1. Complex I inhibits acetic acid- and phenyl-p-benzoquinone
(PBQ)-induced writhing response
In the ﬁrst series of experiments, it was addressed whether the
complex I inhibits writhing response induced by acetic acid or PBQ.
Mice were treated with 0.3–10 mg/kg or 1 mg/kg (s.c.) of complex I
40 min before acetic acid (Fig. 1A) or PBQ (Fig. 1B) injection, respec-
tively. Although there was no statistical difference among the doses of
complex I. The ruthenium NO donor inhibited in a dose-dependent
proﬁle the acetic acid writhing (Fig. 1A). The dose of 0.3 mg/kg of
complex I did not inhibit signiﬁcantly the writhing response. On the
other hand, the doses of 1–10 mg/kg inhibited the writhing response
signiﬁcantly without statistical differences among them (Fig. 1A).
Therefore, the dose of 1 mg/kg of title complex was selected for the
next experiments on overt pain-like behavior. Complex I also inhibited
the PBQ-induced writhing response.3.2. Complex I inhibits complete Freund's adjuvant (CFA)-induced overt
pain-like behavior
Micewere treatedwith complex I 40 min before CFA (10 μL) admin-
istration. The time spent licking the paw (Fig. 2A) and the total number
of paw ﬂinches (Fig. 2B) were evaluated for over 30 min. The dose of
1 mg/kg of ruthenium NO donor inhibited CFA-induced overt pain-
like signiﬁcantly (Fig. 2).malin. Mice received subcutaneous treatment with complex I (1 mg/kg, s.c.) or vehicle
alin was saline. The time spent licking the paw (panel A) and the total number of paw
sults are presented as means±SEM of 6 mice per group, and are representative of 2
malin group (panels A and B) (one-way ANOVA followed by Tukey's test).
Fig. 5. [Ru(bpy)2(NO)SO3](PF6) (complex I) inhibits formalin-induced overt pain-like
behavior by activating the cGMP/PKG/ATP-sensitive K+ channels pathway. Mice
received ODQ (0.3 mg/kg, i.p., 30 min), KT5823 (0.5 μg/animal, i.p., 5 min) or
glybenclamide (Gly; 0.3 mg/kg, p.o., 45 min) (panels A–B; C–D; E–F; respectively) before
of complex I (1 mg/kg,) or vehicle subcutaneous treatment, and after an additional
40 minmice received the formalin (1.5%, 25 μL) intraplantar (i.pl.) stimulus. The intensity
of overt pain-like behavior was evaluated by time spent licking and number of ﬂinches
within 5 min (ﬁrst phase) and between 10 and 30 min (second phase) after formalin
injection. Results are presented as means±SEM of 6mice per group, and are representative
of 2 separate experiments. ⁎Pb0.05 compared to the saline group (panels A–F); #Pb0.05
compared the formalin group (panels A–F); ⁎⁎Pb0.05 compared to complex I group (panels
A–F) (one-way ANOVA followed by Tukey's test).
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Mice were treated with complex I 40 min before capsaicin
(5.2 nmol, 20 μL/paw) administration. The time spent licking the paw
(Fig. 3A) and the total number of paw ﬂinches (Fig. 3B) were evaluated
for over 5 min. The dose of 1 mg/kg of ruthenium NO donor inhibited
capsaicin-induced overt pain-like signiﬁcantly (Fig. 3).3.4. Complex I inhibits formalin-induced overt pain-like behavior
Mice were treated with complex I 40 min before formalin (1.5%,
25 μL/paw) administration. The time spent licking the paw (Fig. 4A)
and the total number of paw ﬂinches (Fig. 4B) were evaluated during
30 min. The dose of 1 mg/kg of complex I inhibited the ﬁrst and second
phases of formalin-induced overt pain-like behavior with a more pro-
nounced effect in the nociception of the second phase of the test,
which was abolished (Fig. 4).
3.5. Complex I inhibits formalin-induced overt pain-like behavior by
activating the GMPc/PKG/KATP signaling pathway
Mice were treated with ODQ (0.3 mg/kg, i.p., 30 min), KT5823
(0.5 μg/animal, i.p., 5 min) or glybenclamide (Gly; 0.3 mg/kg, p.o.,
45 min) (Fig. 5A–B; C–D; and E–F; respectively) before complex I
(1 mg/kg) or vehicle (Saline) treatment, and after an additional time of
40 min mice received the formalin (1.5%, 25 μL/paw) stimulus. The
time spent licking the paw (Fig. 7A, C and E) and the total number of
paw ﬂinches (Fig. 5B, D and F) were evaluated during 30 min. All inhibi-
tors (ODQ, KT5823 and glybenclamide) reversed complex I inhibition of
formalin-induce overt pain-like behavior in the ﬁrst and second phases
of the test. Thus, the inhibition formalin-induced overt pain-like behavior
by complex I depends on the activation of cGMP/PKG/ATP-sensitive
potassium channel signaling pathway. The treatment with ODQ, KT5823
or glybenclamide did not present effect per se (data not shown).
3.6. Complex I inhibits carrageenin-induced mechanical hyperalgesia
and neutrophil recruitment in a dose-dependent manner
Mice were treated with complex I (0.3–3 mg/kg, s.c.) or vehicle
(saline) 40 min before carrageenin (100 μg/paw) stimulus, and the in-
tensity ofmechanical hyperalgesia (Fig. 6A)was evaluated after 1, 3 and
5 h. Afterwards (5 h), animals were sacriﬁced and samples of the sub-
cutaneous plantar tissue were collected for myeloperoxidase (MPO) ac-
tivity determination (Fig. 6B). The dose of 0.3 mg/kg of complex I did
not inhibit carrageenin-induced mechanical hyperalgesia (Fig. 6A). On
the other hand, the dose of 1 mg/kg inhibited at 3 h, and the dose of
3.0 mg/kg inhibited at 1, 3, and 5 h carrageenin-induced mechanical
hyperalgesia (Fig. 6A). Only the dose of 3.0 mg/kg of ruthenium NO
donor inhibited the carrageenin-induced neutrophil recruitment to the
paw skin as determined by MPO assay (Fig. 6B). Based on the results of
Fig. 6, the dose of 3 mg/kgof complex Iwas selected for next experiments.
3.7. Complex I inhibits carrageenin-induced mechanical hyperalgesia
and neutrophil recruitment by activating the cGMP/PKG/ATP-sensitive
potassium channel pathway
Mice were treated with ODQ (0.3 mg/kg, i.p., 30 min), KT5823
(0.5 μg/animal, i.p., 5 min) or glybenclamide (Gly; 0.3 mg/kg, p.o.,
45 min) (Fig. 7A–B; C–D; and E–F; respectively) before complex I
(3 mg/kg) or vehicle (Saline) treatment, and after an additional
time of 40 min mice received the carrageenin (100 μg/paw) stimulus.
The intensity ofmechanical hyperalgesiawas evaluated 1, 3 and 5 h after
inﬂammatory stimulus administration (Fig. 7A, C and E). Subsequently
(5 h), the animals were sacriﬁced and subcutaneous plantar tissue was
collected for MPO activity determination (Fig. 7B, D and F). Complex I
signiﬁcantly inhibited carrageenin-induced mechanical hyperalgesia
and neutrophil recruitment and these effects of ruthenium NO donor
were prevented by the ODQ (Fig. 7A–B), KT5823 (Fig. 7C–D) and
glybenclamide (Fig. 7E–F) treatments. Thus, the inhibition of mechanical
hyperalgesia and neutrophil recruitment by complex I depends on the
activation of cGMP/PKG/ATP-sensitive potassium channel signaling
pathway. The treatment with ODQ, KT5823 or glybenclamide did not
present effect per se (data not shown).
Fig. 6. [Ru(bpy)2(NO)SO3](PF6) (complex I) inhibits carrageenin-induced mechanical hyperalgesia and neutrophil recruitment in a dose-dependent manner. Mice received subcu-
taneous treatment with complex I (0.3–3 mg/kg; s.c.) or vehicle (saline — indicated as zero in panel B) 40 min before carrageenin (100 μg/paw) intraplantar (i.pl.) stimulus. The
intensity of mechanical hyperalgesia was evaluated 1, 3 and 5 h after inﬂammatory stimulus administration with electronic pressure-meter (panel A). The samples of subcutaneous
plantar tissue were collected 5 h after carrageenin stimulus and the myeloperoxidase (MPO) activity was determined by an enzymatic assay (panel B). Results are presented as
means±SEM of 6 mice per group, and are representative of 2 separate experiments. ⁎Pb0.05 compared to the saline group; #Pb0.05 compared the carrageenin group (one-way
ANOVA followed by Tukey's test).
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Nitric oxide (NO) is an intriguing molecule. It mediates many path-
ophysiological processes in which it has complex roles. Evidence sug-
gests that NO may both induce and reduce pain. In the present study,
it was investigated the analgesic effect of the ruthenium NO donor,
[Ru(bpy)2(NO)SO3](PF6) (complex I), which inhibited the overt pain-
like behavior induced by acetic acid, phenyl-p-benzoquinone, complete
Freund's adjuvant (CFA), formalin and capsaicin (Transient receptor
potential cation channel subfamily Vmember 1 [TRPV1] agonist). Com-
plex I also inhibited the overt pain-like behavior, mechanical hyper-
algesia and neutrophil recruitment (myeloperoxidase [MPO] activity)
in a guanylate cyclase, protein kinase G (PKG), and ATP-sensitive potas-
sium channel-dependent manner.
Some drugs under clinical use present analgesic effects by activating
the NO/cGMP/PKG/ATP-sensitive potassium channel signaling pathway
reducing the nociceptive information transmission (Cunha et al., 2010;
Sachs et al., 2004; Tonussi and Ferreira, 1994). This group of drugs in-
cludes diclofenac and morphine (Cunha et al., 2010, 2012; Tonussi
and Ferreira, 1994). The analgesic effect of diclofenac depends on NO
signaling (Tonussi and Ferreira, 1994) and inhibition of cyclooxygenase.
This last mechanism gives its classiﬁcation as non-steroidal anti-
inﬂammatory drug and side effects such as gastric and intestinal ulcers
(Beck et al., 1990). Morphine is an opioid analgesic that is effective in
the majority of painful conditions. The peripheral mechanism of action
of morphine relays in the opioid-receptor dependent activation of the
above mentioned NO signaling pathway (Cunha et al., 2010, 2012).
However, its use is limited by side effects and opioid receptor desensiti-
zation that increases the dose need to obtain analgesia in chronic use
(Carvalho et al., 2011; Devulder et al., 2009), and raising the need of
further drug options. Therefore, the activation of NO signaling pathway
without the inhibition of cyclooxygenase or bypassing the opioid recep-
tors would induce analgesia with reduced side effects.
In this sense, the delivery of NO using ruthenium NO donors could
represent a successful analgesic strategy. There is a wide range of
metal complexes that have biological activities and applications for
diseases, such as cancer (Clarke et al., 1999; Dyson and Sava, 2006;Levina et al., 2009), cardiovascular problems (Bates et al., 1991), arthri-
tis (Forestier, 1935), and parasitosis (Navarro, 2009), and some of these
complexes are commercially available (Tfouni et al., 2012). In fact, the
present results demonstrate the applicability of the novel ruthenium
NO donor [Ru(bpy)2(NO)SO3](PF6) as an analgesic in models of overt
pain-like behavior and mechanical hyperalgesia. The effect of complex
I was dose-dependent indicating that the level of analgesia can be
controlled according to the need. Furthermore, it was observed that
complex I induced analgesia by activating the cGMP/PKG/ATP-sensitive
potassium channel pathway (present data) similarly to morphine and
diclofenac (Cunha et al., 2010, 2012; Tonussi and Ferreira, 1994). In
agreement with this mechanism, other ruthenium NO donors induce
vasorelaxant effects in a soluble guanylate cyclase- and potassium
channels-dependent manner (Lunardi et al., 2007; Pereira et al.,
2011). Furthermore, we speculate that the activation of the cGMP/
PKG/ATP-sensitive potassium channel pathway by complex I is a neuro-
nal events as for morphine, which is also consistent with the inhibition
of the ﬁrst phase of formalin test described as a neuronal phase
(Dubuisson andDennis, 1977; present data). In agreementwith intracel-
lular delivery of NOby complex I, this NO donor induces the relaxation of
rabbit corpus cavernosum and aortic vascular endothelium by activating
intracellular cGMP production since extracellular NO scavengers did not
affect the relaxation induced by complex I (Cerqueira et al., 2008). Com-
plex I also inhibited the abdominal contortions induced by acetic acid
and PBQ. This is consistent with the inhibition of zymosan-induced ab-
dominal contortions by sildenaﬁl by activating NO/cGMP/ATP sensitive
potassium channels (Vale et al., 2007). Therefore, the abdominal contor-
tions behavioral response is susceptible to NO/cGMP/ATP sensitive potas-
sium channels analgesic signaling pathway.
The treatment with complex I also increases the survival of mice in
a model of Paracoccidioides brasiliensis infection with increased IL-10
levels while diminishing TNFα production. These results might be
related to the microbicidal effect of NO released by this compound,
which results in reduced microbial counts and reduced inﬂammation
(Pavanelli et al., 2011). This might be of importance in the context of
pain during infection in which analgesics with anti-inﬂammatory
effects may have a deleterious side effect of facilitating infection
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strated in P. brasiliensis infection model, treatment with complex I
would not impair the host response (Pavanelli et al., 2011). Further-
more, NO inhibits neutrophil recruitment by activating the cGMP/
PKG/ATP sensitive potassium channels signaling pathway (Paula-
Neto et al., 2011). These data corroborate the fact that complex I
reduced the recruitment of inﬂammatory cells to the lung and liver
tissue induced by P. brasiliensis infection (Pavanelli et al., 2011) andthe present ﬁnding that complex I inhibited carrageenin-induced neutro-
phil recruitment to the paw skin as determined by the myeloperoxidase
activity. The neutrophils recruited to the inﬂammatory foci contribute
to pain by further producing nociceptivemolecules such as prostaglandin
E2 and leukotrieneB4 (Cunha et al., 2008;Guerrero et al., 2008; Verri et al.,
2009). Therefore, inhibition of neutrophil recruitment by complex Imight
also be a contributing mechanism to its analgesic activity.
In addition to NO delivery, ruthenium is a molecule used to form
complexes with varied activities. For instance, there is evidence that
ruthenium complexes form non-selective TRP inhibitors as observed
for ruthenium red (Liang et al., 2011). In this sense, it was observed
that complex I inhibited capsaicin-induced overt pain-like behavior,
indicating the blockade of TRPV1-induced nociception as an analgesic
mechanism of complex I (Caterina et al., 1997). This effect seems to
be NO-independent and ruthenium-dependent since ruthenium is
the common feature between ruthenium red (does not present NO
in its structure) and complex I. Furthermore, TRPV1 channels had
been implicated in the nociception in some of the models tested in
the present study including formalin, CFA and carrageenin (Kanai et
al., 2006), suggesting that blocked of TRPV1 may be an additional
underlying analgesic mechanism of complex I.
Corroborating the potential applicability of ruthenium NO donor
complexes, they present low cytotoxicity (Tfouni et al., 2012). Herein,
we observed that the treatment with complex I at an analgesic dose
(3 mg/kg) did not alter the response in the rota-rod test within 5 h
(time of carrageenin test), indicating that there was no motor impair-
ment, muscle relaxing or acute toxicity in mice. Furthermore, there
was no alteration in AST (aspartate aminotransferase) and ALT (alanine
aminotransferase) plasma levels by treatmentwith complex I, indicating
no acute liver damage (data not shown).
Concluding, this is theﬁrst study to demonstrate that [Ru(bpy)2(NO)
SO3](PF6) induces analgesia by blocking TRPV1 agonist-induced
nociception and activating the cGMP/PKG/ATP-sensitive potassium
channel pathway.Acknowledgments
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